Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals

Yoshihiro Sumita, Hiroshi Nouda, Eiko Tada, Tsuneo Kohzuki, Masuhiro Kato, Takao Okuda, Masato Fukasawa

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The pharmacokinetics of meropenem (MEPM), a new carbapenem antibiotic, were studied in mice, rats, guinea pigs, rabbits, dogs and monkeys. The peak plasma levels of MEPM intravenously administered at a dose of 20 mg/kg were 64.0 µg/ml in mice, 99.8 µg/ml in rats, 82.2 µg/ml in guinea pigs, 99.2 µg/ml in rabbits, 133 µg/ml in dogs and 93.4 µg/ml in monkeys. The plasma half-lives of MEPM were 4.5 min in mice, 3.0 min in rats, 12.9 min in guinea pigs, 20.8 min in rabbits, 40.8 min in dogs and 30.9 min in monkeys; the plasma half-lives in mice and rats were about one-half or one-third of those of imipenem (IPM), although MEPM and IPM showed almost the same half-lives in guinea pigs. The urinary excretion rates of MEPM were 34.1% of the dose in mice, 25.0% in rats, 42.5% in guinea pigs, 34.6% in rabbits, 49.1% in dogs and 25.7% in monkeys. A dose-proportionality study was conducted with intravenous doses of 5 to 50 mg/kg in mice and guinea pigs. The AUCs were linearly proportional to doses. These findings suggest that tissue distribution and the excretion pathway were independent of administration dose. The tissue levels of MEPM given to mice, rats and guinea pigs by the intravenous route at a dose of 20 mg/kg were the highest in plasma, followed in descending order by liver, kidney, heart, lung and spleen in mice, and kidney, liver, heart and spleen in rats. In guinea pigs, the order was plasma, lung, heart, kidney, spleen and liver. The half-lives of MEPM in 10% lung homogenate from various experimental animals were 84 min in mice, 42 min in rats, 1210 min in guinea pigs, 247 min in rabbits, 1000 min in dogs and 209 min in monkeys. The stability of MEPM against renal dehydropeptidase-I (DHP-I) varied greatly with the animal source of the enzyme. MEPM was more easily hydrolyzed than IPM by DHP-I from mice, rabbits and monkeys, but was more stable than IPM in guinea pigs, dogs and human DHP-I. The serum protein bindings of MEPM were 33.8% in mice, 14.1% in rats, 15.8% in guinea pigs, 21.2% in rabbits, 7.5% in dogs, 7.9% in monkeys and 13% in humans.

Original languageEnglish
Pages (from-to)123-131
Number of pages9
JournalChemotherapy
Volume40
DOIs
Publication statusPublished - Jan 1 1992
Externally publishedYes

Fingerprint

meropenem
Carbapenems
Laboratory Animals
Guinea Pigs
Pharmacokinetics
Haplorhini
Dogs
Rabbits
Imipenem
dipeptidase 1
Kidney
Spleen
Lung
Liver

Keywords

  • Meropenem

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals. / Sumita, Yoshihiro; Nouda, Hiroshi; Tada, Eiko; Kohzuki, Tsuneo; Kato, Masuhiro; Okuda, Takao; Fukasawa, Masato.

In: Chemotherapy, Vol. 40, 01.01.1992, p. 123-131.

Research output: Contribution to journalArticle

Sumita, Yoshihiro ; Nouda, Hiroshi ; Tada, Eiko ; Kohzuki, Tsuneo ; Kato, Masuhiro ; Okuda, Takao ; Fukasawa, Masato. / Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals. In: Chemotherapy. 1992 ; Vol. 40. pp. 123-131.
@article{c7e673cee922494dba157208d4f50c79,
title = "Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals",
abstract = "The pharmacokinetics of meropenem (MEPM), a new carbapenem antibiotic, were studied in mice, rats, guinea pigs, rabbits, dogs and monkeys. The peak plasma levels of MEPM intravenously administered at a dose of 20 mg/kg were 64.0 µg/ml in mice, 99.8 µg/ml in rats, 82.2 µg/ml in guinea pigs, 99.2 µg/ml in rabbits, 133 µg/ml in dogs and 93.4 µg/ml in monkeys. The plasma half-lives of MEPM were 4.5 min in mice, 3.0 min in rats, 12.9 min in guinea pigs, 20.8 min in rabbits, 40.8 min in dogs and 30.9 min in monkeys; the plasma half-lives in mice and rats were about one-half or one-third of those of imipenem (IPM), although MEPM and IPM showed almost the same half-lives in guinea pigs. The urinary excretion rates of MEPM were 34.1{\%} of the dose in mice, 25.0{\%} in rats, 42.5{\%} in guinea pigs, 34.6{\%} in rabbits, 49.1{\%} in dogs and 25.7{\%} in monkeys. A dose-proportionality study was conducted with intravenous doses of 5 to 50 mg/kg in mice and guinea pigs. The AUCs were linearly proportional to doses. These findings suggest that tissue distribution and the excretion pathway were independent of administration dose. The tissue levels of MEPM given to mice, rats and guinea pigs by the intravenous route at a dose of 20 mg/kg were the highest in plasma, followed in descending order by liver, kidney, heart, lung and spleen in mice, and kidney, liver, heart and spleen in rats. In guinea pigs, the order was plasma, lung, heart, kidney, spleen and liver. The half-lives of MEPM in 10{\%} lung homogenate from various experimental animals were 84 min in mice, 42 min in rats, 1210 min in guinea pigs, 247 min in rabbits, 1000 min in dogs and 209 min in monkeys. The stability of MEPM against renal dehydropeptidase-I (DHP-I) varied greatly with the animal source of the enzyme. MEPM was more easily hydrolyzed than IPM by DHP-I from mice, rabbits and monkeys, but was more stable than IPM in guinea pigs, dogs and human DHP-I. The serum protein bindings of MEPM were 33.8{\%} in mice, 14.1{\%} in rats, 15.8{\%} in guinea pigs, 21.2{\%} in rabbits, 7.5{\%} in dogs, 7.9{\%} in monkeys and 13{\%} in humans.",
keywords = "Meropenem",
author = "Yoshihiro Sumita and Hiroshi Nouda and Eiko Tada and Tsuneo Kohzuki and Masuhiro Kato and Takao Okuda and Masato Fukasawa",
year = "1992",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.40.Supplement1_123",
language = "English",
volume = "40",
pages = "123--131",
journal = "Chemotherapy",
issn = "0009-3165",

}

TY - JOUR

T1 - Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals

AU - Sumita, Yoshihiro

AU - Nouda, Hiroshi

AU - Tada, Eiko

AU - Kohzuki, Tsuneo

AU - Kato, Masuhiro

AU - Okuda, Takao

AU - Fukasawa, Masato

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The pharmacokinetics of meropenem (MEPM), a new carbapenem antibiotic, were studied in mice, rats, guinea pigs, rabbits, dogs and monkeys. The peak plasma levels of MEPM intravenously administered at a dose of 20 mg/kg were 64.0 µg/ml in mice, 99.8 µg/ml in rats, 82.2 µg/ml in guinea pigs, 99.2 µg/ml in rabbits, 133 µg/ml in dogs and 93.4 µg/ml in monkeys. The plasma half-lives of MEPM were 4.5 min in mice, 3.0 min in rats, 12.9 min in guinea pigs, 20.8 min in rabbits, 40.8 min in dogs and 30.9 min in monkeys; the plasma half-lives in mice and rats were about one-half or one-third of those of imipenem (IPM), although MEPM and IPM showed almost the same half-lives in guinea pigs. The urinary excretion rates of MEPM were 34.1% of the dose in mice, 25.0% in rats, 42.5% in guinea pigs, 34.6% in rabbits, 49.1% in dogs and 25.7% in monkeys. A dose-proportionality study was conducted with intravenous doses of 5 to 50 mg/kg in mice and guinea pigs. The AUCs were linearly proportional to doses. These findings suggest that tissue distribution and the excretion pathway were independent of administration dose. The tissue levels of MEPM given to mice, rats and guinea pigs by the intravenous route at a dose of 20 mg/kg were the highest in plasma, followed in descending order by liver, kidney, heart, lung and spleen in mice, and kidney, liver, heart and spleen in rats. In guinea pigs, the order was plasma, lung, heart, kidney, spleen and liver. The half-lives of MEPM in 10% lung homogenate from various experimental animals were 84 min in mice, 42 min in rats, 1210 min in guinea pigs, 247 min in rabbits, 1000 min in dogs and 209 min in monkeys. The stability of MEPM against renal dehydropeptidase-I (DHP-I) varied greatly with the animal source of the enzyme. MEPM was more easily hydrolyzed than IPM by DHP-I from mice, rabbits and monkeys, but was more stable than IPM in guinea pigs, dogs and human DHP-I. The serum protein bindings of MEPM were 33.8% in mice, 14.1% in rats, 15.8% in guinea pigs, 21.2% in rabbits, 7.5% in dogs, 7.9% in monkeys and 13% in humans.

AB - The pharmacokinetics of meropenem (MEPM), a new carbapenem antibiotic, were studied in mice, rats, guinea pigs, rabbits, dogs and monkeys. The peak plasma levels of MEPM intravenously administered at a dose of 20 mg/kg were 64.0 µg/ml in mice, 99.8 µg/ml in rats, 82.2 µg/ml in guinea pigs, 99.2 µg/ml in rabbits, 133 µg/ml in dogs and 93.4 µg/ml in monkeys. The plasma half-lives of MEPM were 4.5 min in mice, 3.0 min in rats, 12.9 min in guinea pigs, 20.8 min in rabbits, 40.8 min in dogs and 30.9 min in monkeys; the plasma half-lives in mice and rats were about one-half or one-third of those of imipenem (IPM), although MEPM and IPM showed almost the same half-lives in guinea pigs. The urinary excretion rates of MEPM were 34.1% of the dose in mice, 25.0% in rats, 42.5% in guinea pigs, 34.6% in rabbits, 49.1% in dogs and 25.7% in monkeys. A dose-proportionality study was conducted with intravenous doses of 5 to 50 mg/kg in mice and guinea pigs. The AUCs were linearly proportional to doses. These findings suggest that tissue distribution and the excretion pathway were independent of administration dose. The tissue levels of MEPM given to mice, rats and guinea pigs by the intravenous route at a dose of 20 mg/kg were the highest in plasma, followed in descending order by liver, kidney, heart, lung and spleen in mice, and kidney, liver, heart and spleen in rats. In guinea pigs, the order was plasma, lung, heart, kidney, spleen and liver. The half-lives of MEPM in 10% lung homogenate from various experimental animals were 84 min in mice, 42 min in rats, 1210 min in guinea pigs, 247 min in rabbits, 1000 min in dogs and 209 min in monkeys. The stability of MEPM against renal dehydropeptidase-I (DHP-I) varied greatly with the animal source of the enzyme. MEPM was more easily hydrolyzed than IPM by DHP-I from mice, rabbits and monkeys, but was more stable than IPM in guinea pigs, dogs and human DHP-I. The serum protein bindings of MEPM were 33.8% in mice, 14.1% in rats, 15.8% in guinea pigs, 21.2% in rabbits, 7.5% in dogs, 7.9% in monkeys and 13% in humans.

KW - Meropenem

UR - http://www.scopus.com/inward/record.url?scp=0026683063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026683063&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.Supplement1_123

DO - 10.11250/chemotherapy1953.40.Supplement1_123

M3 - Article

AN - SCOPUS:0026683063

VL - 40

SP - 123

EP - 131

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -